1. Introduction {#s0005}
===============

Cervical cancer is the most common cancer in women in East Africa ([@b0005]), and was recognized as an "AIDS-defining cancer" early in the HIV epidemic ([@b0010]). Even in the era of antiretroviral therapy (ART), the incidence of cervical cancer is at least four times higher among HIV-positive than HIV-negative women ([@b0015]). Almost all cases of cervical cancer are caused by oncogenic strains of the human papillomavirus (HPV) ([@b0020]). Women with HIV however are more likely to experience persistent HPV infection, development and persistence of cervical dysplasia, and more rapid progression to cancer ([@b0025]). Recent studies from upper-middle-income economies, as defined by the World Bank, ([@b0030]) have begun to explore the impact of HIV infection on survival in cervical cancer patients and shown differing results ([@b0035], [@b0040], [@b0045], [@b0050]).

Uganda is a low-income economy ([@b0030]) with an estimated adult HIV prevalence of 7.1% ([@b0060]). It has a well-established national cancer center that has had the ability to provide surgery, radiotherapy, and chemotherapy. However, the healthcare system and its patients often lack the resources to initiate or complete treatment after a cancer diagnosis. Understanding the presentation and outcomes of cervical cancer in patients who seek care in these environments can better inform care delivery. The impact of HIV on cervical cancer survival has not yet been reported in low-income economies. Therefore the aims of this study are to compare cervical cancer stage at diagnosis between HIV-positive and HIV-negative individuals and to characterize the relationship between HIV disease and cervical cancer survival in Uganda.

2. Materials and methods {#s0010}
========================

2.1. Study design and participants {#s0015}
----------------------------------

We conducted a prospective cohort study of cervical cancer patients diagnosed between August 2013 and August 2015 at the Uganda Cancer Institute (UCI) in Kampala, Uganda, which is the country's only national cancer referral hospital. Adult women undergoing diagnostic workup for suspected cervical cancer were referred to the study for assessment. Patients were eligible for inclusion if they (1) had pathologically confirmed cervical cancer, (2) underwent their initial evaluation at the UCI, and (3) committed to attending all study visits during the three-year observation period. Written informed consent was obtained from all subjects.

For a complete description of materials and methods, see Supplemental Content 1.

2.2. Data collection {#s0020}
--------------------

On enrollment, a standard set of assessments was made for each participant, including medical and demographic history, physical exam, blood draw, and tumor biopsy. Participants returned for follow-up visits to review treatment history and health status 6, 12, 24, and 36 months after enrollment. Patients who received treatment were considered to have received adequate radiation therapy if their combined external-beam and brachytherapy equivalent dose (EQD2) was at least 73.75 Gy. This is the EQD2 dose for 45 Gy of external-beam radiation delivered over 15 fractions followed by 25 Gy of low-dose rate brachytherapy delivered in one fraction, which was the standard definitive treatment regimens at the UCI

2.3. Statistical analysis {#s0025}
-------------------------

The primary exposure of interest was HIV serostatus, as determined by HIV antibody testing, assessed using the enrollment blood draw.

The primary outcome of interest was overall survival (OS), which was measured from enrollment to the date of death or last known contact. Patients were censored at the time of their last known contact or the conclusion of study follow-up (September 10, 2016). The Kaplan-Meier method was used to compare OS in HIV-positive and HIV-negative cervical cancer patients using the log-rank test. A Cox proportional hazards model was used to determine the adjusted association between HIV serostatus and OS. A directed acyclic graph (DAG) illustrating causal assumptions between key clinicopathologic characteristics was developed to determine the role of each variable in this analysis and reasons for inclusion in the multivariable Cox model (see Supplemental Content 2). As seen in the DAG, only age at diagnosis met criteria as a potential confounder. While FIGO stage does not meet the criteria as a potential confounder, it was included in our model to assess its role as a mediator. Because almost all cervical cancer tumors in Uganda are squamous histology and poorly or undifferentiated grade, these factors were not included in the final model. An exploratory analysis was performed to examine the potential role of hemoglobin as a mediator (see Supplemental Content 3).

The secondary outcome of interest was FIGO stage at diagnosis. Stages III and IV were considered late. Poisson regression using robust standard errors was used to calculate prevalence ratios (PR) as measures of the association between HIV serostatus and late stage of cancer at diagnosis, adjusted for age, number of live births, and cost of transportation to the UCI.

3. Results {#s0030}
==========

From August 2013 to August 2015, 149 women enrolled in this study. There were 53 (35.6%) HIV-positive and 96 (64.4%) HIV-negative participants. The demographic, clinical, and treatment characteristics of the study population are shown in [Table 1](#t0005){ref-type="table"}. The HIV-positive group was younger than the HIV-negative group (median age 44 and 54 respectively) and reported fewer live births. FIGO stage distribution was similar. HIV-positive individuals had lower median CD4 count at enrollment (373 versus 926 cells/mm^3^) compared to HIV-negative individuals. The majority of HIV-positive individuals were enrolled in care for HIV, using ART, and with undetectable viral loads.Table 1Selected cervical cancer patient demographic, clinical and treatment characteristics, cervical cancer prognosis study, Kampala, Uganda, 2013--2015.CharacteristicHIV-negative, \# (%)\
(n = 96)HIV-positive, \# (%)\
(n = 53)Median age (IQR), years54 (47--62)44 (39--48)Highest education completed- None25 (34)8 (19)- Primary42 (57)22 (52)- Secondary or greater7 (9)12 (29)- Unknown**\***2211  Tobacco use- Lifelong non-smoker90 (94)51 (98)- Current smoker1 (1)0 (0)- Former smoker5 (5)1 (2)- Unknown**\***01  Live births- 01 (1)0 (0)- 1--312 (13)20 (38)- 4--733 (34)24 (45)- 8+50 (52)9 (17)Median BMI (IQR)23 (20--27)23 (19--25)  ECOG performance status- 02 (2)0 (0)- 180 (84)48 (91)- 28 (8)4 (7)- 36 (6)1 (2)  Transport cost to UCI (USh)- ≤20,00050 (52)42 (79)- 21,000--40,00026 (27)8 (15)- 41,000--60,00016 (17)3 (6)- \>60,0004 (4)0 (0)  FIGO stage- I12 (12)10 (19)- II47 (49)26 (49)- III33 (35)15 (28)- IV4 (4)2 (4)  Tumor histology- Squamous95 (95)48 (90)- Adenocarcinoma4 (4)4 (8)- Other1 (1)1 (2)  Tumor grade- Well differentiated1 (1)5 (10)- Moderately differentiated22 (23)13 (25)- Poorly/undifferentiated71 (76)33 (65)- Unknown22  Type of initial treatment- Chemoradiation21 (25)10 (21)- Chemotherapy only1 (1)1 (2)- Radiation therapy only40 (49)27 (56)- Surgery only0 (0)1 (2)- Surgery + adjuvant treatment[a](#tblfn2){ref-type="table-fn"}0 (0)2 (4)- No treatment21 (25)7 (15)- Unknown**\***135  Total radiation therapy received- \<73.75 Gy25 (42)15 (43)- ≥73.75 Gy34 (58)20 (57)- Unknown**\***22- Did not receive upfront radiotherapy3516Median baseline hemoglobin[b](#tblfn3){ref-type="table-fn"} (IQR), g/dL12.0 (9.9--12.9)10.5 (8.6--12.5)Median CD4 at enrollment, (IQR), cells/mm^3^926 (639--1045)373 (300--502)Enrolled in HIV care services at enrollment--- Yes--45 (88)- No--6 (12)- Unknown**\***2  Duration of HIV infection- \<1 year--8 (16)− 1--5 years--17 (33)- \>5 years--26 (51)- Unknown[\*](#tblfn1){ref-type="table-fn"}--2  HIV plasma RNA level at enrollment- \<500 copies/mL--41 (77)- ≥500 copies/mL--12 (23)  HAART use at enrollment- No--12 (23)- Yes--41 (77)[^1][^2][^3][^4]

3.1. HIV associations with stage at diagnosis {#s0035}
---------------------------------------------

Seventeen (32.1%) HIV-positive and 37 (38.5%) HIV-negative patients presented with late stage cervical cancer (FIGO stage III-IV). [Table 2](#t0010){ref-type="table"} shows the unadjusted and adjusted PRs for late stage at cancer diagnosis for HIV serostatus, age, number of live births, and cost of transportation to the UCI. The unadjusted PR for late stage at cancer diagnosis comparing HIV-positive with HIV-negative participants was 0.8 (95%CI 0.5--1.3); the adjusted PR was 1.0 (95%CI 0.6--1.8).Table 2Univariable and multivariable associations of selected characteristics with late stage at cervical cancer diagnosis, Kampala, Uganda, 2013--2015.[\*](#tblfn4){ref-type="table-fn"}CharacteristicUnivariable analysis PR (95%CI)\
(n = 149)Multivariable analysis[\*\*](#tblfn5){ref-type="table-fn"}PR (95%CI)\
(n = 149)HIV serostatus- HIV-negative1.0 (reference)1.0 (reference)- HIV-positive0.8 (0.5--1.3)1.0 (0.6--1.8)  Age*(Per 10-year age increase)*1.2 (1.0--1.4)1.1 (0.9--1.3)  Live births*(Per each additional 1 live birth)*1.2 (1.0--1.1)1.0 (0.9--1.1)  Transport cost to UCI (USh)- ≤20,0001.0 (reference)1.0 (reference)- 21,000--40,0000.7 (0.3--1.3)0.7 (0.3--1.3)- 41,000--60,0001.5 (0.9--2.4)1.4 (0.8--2.4)- \>60,0002.1 (1.1--3.9)1.9 (0.9--4.0)[^5][^6][^7]

[Table 3](#t0015){ref-type="table"} shows HIV-specific treatment characteristics by FIGO stage at diagnosis among the HIV-positive patients. Persons presenting with late-stage disease tended to have lower CD4 cell counts, but similar HIV plasma concentrations.Table 3HIV-specific treatment characteristics by cervical cancer stage at diagnosis among HIV-positive patients, Kampala, Uganda, 2013--2015.CharacteristicEarly stage, % (\#)\
(n = 36)Late stage, % (\#)\
(n = 17)Duration of HIV infection- \<1 year6 (17)2 (12)− 1--5 years10 (29)7 (44)- \>5 years19 (54)7 (44)- Unknown[\*](#tblfn6){ref-type="table-fn"}11  CD4 T-cell count at enrollment- \>500 cells/mm39 (25)5 (29)− 201--500 cells/mm324 (67)8 (47)− 0--200 cells/mm33 (8)4 (24)  HIV plasma RNA level at enrollment- \<500 copies/mL27 (75)14 (82)- ≥500 copies/mL9 (25)3 (18)HAART use at enrollment- No8 (22)4 (24)- Yes28 (78)13 (76)  Enrolled in HIV care services at enrollment- No3 (9)3 (18)- Yes31 (91)14 (82)- Unknown[\*](#tblfn6){ref-type="table-fn"}20[^8]

3.2. Treatment characteristics {#s0040}
------------------------------

Among patients for whom treatment status was known, a greater proportion of HIV-positive individuals received cancer treatment compared to HIV-negative individuals (85% and 75% respectively), the majority of which included radiation. Among those who received radiation as part of their upfront therapy, a similar proportion of HIV-positive and HIV-negative patients received adequate radiation therapy (57% and 58% respectively) and a smaller proportion of HIV-positive individuals received concurrent chemotherapy (27% vs 34%).

3.3. HIV associations with overall survival {#s0045}
-------------------------------------------

The median follow-up was 14.8 months among the entire cohort and 18.9 months among those alive and not lost to follow-up. One HIV-positive and one HIV-negative participant were lost to follow-up. There were 35 deaths among HIV-positive and 45 deaths among HIV-negative individuals. One-year survival was 65% (95%CI 51--77%) among HIV-positive and 69% (95%CI 58--77%) among HIV-negative participants. Two-year survival was 30% (95%CI 17--44%) among HIV-positive and 51% (95%CI 39--62%) among HIV-negative patients. The median survival was 18.3 months---14.7 months among HIV-positive individuals and 24.3 months among HIV-negative individuals. As seen in [Fig. 1](#f0005){ref-type="fig"}, HIV-positive patients had shorter unadjusted OS compared to HIV-negative patients, with a divergence in survival curves starting at 12 months.Fig. 1Kaplan-Meier plot of overall cervical cancer survival, stratified by HIV serostatus, Kampala, Uganda, 2013--2015. Risk table below plot shows number at risk at each labeled time point and number of deaths (in parentheses) during each labeled time interval.

[Table 4](#t0020){ref-type="table"} shows the univariable and multivariable Cox regression analyses of characteristics in relation to OS. In univariable analysis, HIV infection (HR 1.6, 95%CI 1.0--2.4) and late FIGO stage (HR 2.3, 95%CI 1.5--3.6) were associated with an increased hazard of death. After adjusting for age and FIGO stage, there was a weaker association between HIV infection and OS (HR 1.3, 95%CI 0.8--2.2).Table 4Univariable and multivariable associations of selected characteristics with overall survival among cervical cancer patients, Kampala, Uganda, 2013--2015.CharacteristicUnivariable analysis HR (95%CI)Multivariable analysis[\*](#tblfn7){ref-type="table-fn"}HR (95%CI)HIVSeroStatus- HIV-negative1.0 (reference)1.0 (reference)- HIV-positive1.6 (1.0--2.4)1.3 (0.8--2.2)  FIGO stage- Early (stage I-II)1.0 (reference)1.0 (reference)- Late (stage III-IV)2.3 (1.5--3.6)2.8 (1.7--4.4)[^9][^10]

4. Discussion {#s0050}
=============

In this prospective study, we found that among newly diagnosed Ugandan cervical cancer patients, mortality was high and optimal treatment rates were low, irrespective of HIV status. While the stage distribution was similar between HIV-positive and HIV-negative women, there was an approximately 60% poorer survival in HIV-positive patients, with a divergence in survival curves starting at 12 months. A multivariable model that included age and FIGO stage showed a weaker association between HIV serostatus and hazard of death, most likely reflecting a confounding effect of age. In our analyses, neither stage nor hemoglobin were found to be mediating factors.

This is one of the first studies to examine the relationship between HIV status and cervical cancer survival in a low-income economy. Findings from our study are consistent with those reported from upper-middle-income countries, such as Botswana and Brazil, where most HIV-positive individuals studied were also on ART. In an early Botswana study, investigators found that HIV infection nearly doubled the adjusted hazard of death after a cervical cancer diagnosis ([@b0045]). In Brazil, no differences in survival were noted at one year, but after one year, HIV infection doubled the stage-adjusted hazards of death. Survival curves from the Brazilian cohort showed a similar divergence at one year as observed in our study ([@b0040]). In South Africa, two- and five-year unadjusted survival was significantly worse in HIV-positive individuals even when excluding patients with low CD4 counts ([@b0050]). Possible explanations include earlier cancer recurrence (seen in the Brazilian cohort and not measured in our cohort), more rapid progression after a partial response, and more frequent late toxicities (not measured in any of the cohorts). In many lower resource settings, post-treatment assessments are often not performed, making it difficult to distinguish between those who have recurred after a complete response versus those who have progressed after a partial response---scenarios in which HIV infection may have differing impact.

Interestingly, a subsequent publication from the group in Botswana reported on cervical cancer patients who received curative intent concurrent chemotherapy and radiation therapy ([@b0035]). This was a more highly selected population compared to other studies: median ART treatment duration was longer (7 years), median CD4 count was higher (481 cells/mm^3^), and a higher proportion of individuals completed treatment. In this study, HIV infection was not associated with 2-year OS.

The majority of people who received radiation therapy in our study did not receive adequate radiotherapy nor concurrent chemotherapy, which has been shown to improve survival ([@b0065]). This was a similar problem in other lower-resourced settings, such as the earlier Botswana study where only 48% of women in Botswana treated with curative intent completed the recommended radiation therapy ([@b0045]). Even in the later Botswana study, only 76% of HIV-positive patients completed brachytherapy ([@b0035]).

In addition to cancer treatment, a mediator of poorer survival associated with HIV infection could include subtle differences in immune status. While the median CD4 count at enrollment (373 cells/mm^3^) among HIV-positive individuals in our study was above the threshold at which most severe opportunistic infections are considered a risk, this was still far below the median CD4 count among HIV-negative individuals (926 cells/mm^3^). The authors from the second Botswana study suggest that outcomes by HIV status were similar in part because HIV infections were well-controlled in their population. However, the CD4 counts and duration of ART treatment were only slightly better than in our study and in the earlier Botswana study ([@b0035], [@b0045]). Perhaps these small differences in immune status are sufficient to drive variation in outcome. Increasing evidence supports the adaptive immune system's role in ongoing clinical benefits from cancer therapy ([@b0070]). Immune dysfunction and T-cell depletion characterize HIV infection ([@b0075]), and subtle functional immune deficits may potentially persist in women with optimally-treated HIV infection ([@b0080], [@b0085]). Furthermore, T-cell responses in the peripheral blood are not necessarily reflective of mucosal immunity, such as in the cervix ([@b0085]), and mucosal CD4 cell populations in HIV-positive women may not recover after initiating ART ([@b0080]).

Our study is limited by a small sample size. While our results may be applicable to patients who present to the UCI for care, they may not reflect the general population in Uganda where ART coverage is 57%, compared to 77% in our study ([@b0060]). Nevertheless, our study population represents a group of patients among whom effort could be made to substantially improve survival.

This is one of the first studies on cervical cancer survival in a low-income economy, where it is important to better define optimal interventions. With the majority of new cervical cancer cases occurring in low- and middle-income economies, it is imperative to continue detailed studies of the natural history of cervical cancer and explore novel treatment and retention strategies in these populations.
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The following are the Supplementary data to this article:Supplementary Fig. 1Directed Acyclic Graph illustrating causal assumptions applied to potential confounding and mediating variables in a cohort of patients with cervical cancer where the exposure of interest is HIV serostatus and the outcome of interest is overall survival. Arrows represent direction of causal effects between two variables. The black pathway represents the hypothesized association between HIV and survival; the red pathway represents a potential confounding relationship; green pathways represent potential mediating relationships.

Supplementary data 1

Supplementary data 2Mediation analysis showing relationship between potential mediator and HIV serostatus; and whether the association between HIV and cervical cancer is diminished when mediator is added into the regression model.
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[^1]: Abbreviations: IQR = interquartile range; UCI = Uganda Cancer Institute; USh = Ugandan shillings; ECOG = Eastern Cooperative Oncology Group.

[^2]: Missing data are shown as separate category for categorical variables, but percentages were calculated among non-missing data only.

[^3]: 1 patient received radiation therapy; 1 patient received concurrent chemoradiation.

[^4]: Baseline hemoglobin was not available for 34 (35%) of HIV-negative and 16 (30%) of HIV-positive patients.

[^5]: Abbreviations: PR = prevalence ratio; USh = Ugandan Shillings.

[^6]: In the model, 54 patients were late stage at diagnosis, and 95 were earlier stage at diagnosis.

[^7]: Multivariable analysis adjusted for HIV serostatus, age, number of live births, transport cost.

[^8]: Missing data are shown as separate category for categorical variables, but percentages were calculated among non-missing data only.

[^9]: Abbreviations: HR = hazard ratio; CI = confidence interval; FIGO = International Federation of Gynecology and Obstetrics.

[^10]: Adjusted for HIV serostatus, age, and FIGO stage.
